Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

Pharmacogenetic response to antidepressants in a multicase family with affective disorder.

O'Reilly RL, Bogue L, Singh SM.

Biol Psychiatry. 1994 Oct 1;36(7):467-71.

PMID:
7811843
2.

The role of pharmacogenetics in the treatment of depression and anxiety disorders.

Schosser A, Kasper S.

Int Clin Psychopharmacol. 2009 Nov;24(6):277-88. doi: 10.1097/YIC.0b013e3283306a2f. Review.

PMID:
19738481
3.

Moclobemide: therapeutic use and clinical studies.

Bonnet U.

CNS Drug Rev. 2003 Spring;9(1):97-140. Review.

4.

Reversible monoamine oxidase-A inhibitors in resistant major depression.

Nolen WA, Hoencamp E, Bouvy PF, Haffmans PM.

Clin Neuropharmacol. 1993;16 Suppl 2:S69-76. Review.

PMID:
8313400
5.

Pharmacogenetic insights into depression and antidepressant response: does sex matter?

Pitychoutis PM, Zisaki A, Dalla C, Papadopoulou-Daifoti Z.

Curr Pharm Des. 2010;16(20):2214-23. Review.

PMID:
20459391
6.

New approaches to antidepressant drug discovery: beyond monoamines.

Berton O, Nestler EJ.

Nat Rev Neurosci. 2006 Feb;7(2):137-51. Review.

PMID:
16429123
7.

Pharmacogenomics of antidepressant drugs.

Horstmann S, Binder EB.

Pharmacol Ther. 2009 Oct;124(1):57-73. doi: 10.1016/j.pharmthera.2009.06.007. Epub 2009 Jun 27. Review.

PMID:
19563827
8.

Treatment of depression--newer pharmacotherapies.

Mulrow CD, Williams JW Jr, Trivedi M, Chiquette E, Aguilar C, Cornell JE, Badgett R, Noël PH, Lawrence V, Lee S, Luther M, Ramirez G, Richardson WS, Stamm K.

Psychopharmacol Bull. 1998;34(4):409-795. Review.

PMID:
10513454
9.

Pharmacogenomics and antidepressant drugs.

Binder EB, Holsboer F.

Ann Med. 2006;38(2):82-94. Review.

PMID:
16581694
10.

Status of treatment of depression.

Broquet KE.

South Med J. 1999 Sep;92(9):846-56. Review.

PMID:
10498158
11.
12.

Severe depression: is there a best approach?

Sonawalla SB, Fava M.

CNS Drugs. 2001;15(10):765-76. Review.

PMID:
11602003
13.

[Use of antidepressant drugs in schizophrenic patients with depression].

Micallef J, Fakra E, Blin O.

Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. Review. French.

PMID:
16910628
15.
16.

New approaches to antidepressant drug design: cytokine-regulated pathways.

Nishida A, Miyaoka T, Inagaki T, Horiguchi J.

Curr Pharm Des. 2009;15(14):1683-7. Review.

PMID:
19442181
17.

Antidepressant drug selection: criteria and options.

Preskorn SH.

J Clin Psychiatry. 1994 Sep;55 Suppl A:6-22; discussion 23-4, 98-100. Review.

PMID:
7961544
18.

Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review.

Adli M, Baethge C, Heinz A, Langlitz N, Bauer M.

Eur Arch Psychiatry Clin Neurosci. 2005 Dec;255(6):387-400. Epub 2005 Apr 29. Review.

PMID:
15868067
19.

[Efficacy of atypical antipsychotics in depressive syndromes].

Quintin P, Thomas P.

Encephale. 2004 Nov-Dec;30(6):583-9. Review. French.

PMID:
15738862
20.

[Combining antidepressants: a useful strategy for therapy resistant depression?].

Schmauss M, Messer T.

Fortschr Neurol Psychiatr. 2009 Jun;77(6):316-25. doi: 10.1055/s-0028-1109338. Epub 2009 May 4. Review. German.

PMID:
19415584

Supplemental Content

Support Center